Molecular Formula | C3H12NNaO7P2 |
Molar Mass | 259.07 |
Melting Point | 300°C |
Boling Point | 658.7°C at 760 mmHg |
Flash Point | 352.2°C |
Solubility | H2O: 28mg/mL |
Vapor Presure | 3.79E-20mmHg at 25°C |
Appearance | solid |
Color | white |
Merck | 14,7003 |
Storage Condition | 2-8°C |
Stability | Hygroscopic |
Physical and Chemical Properties | Melting point 300°C |
Use | For the treatment of hypercalcemia and osteoporosis |
In vitro study | In human osteoblasts, Pamidronate increased OPG mRNA levels and protein secretion in a dose-dependent manner up to 2-to 3-fold, with maximal effect after 72 hours of 1 μm treatment. Pamidronate prevents the inhibitory effect of the glucocorticoid dexamethasone on OPG mRNA and protein production. Pamidronate induces type I collagen secretion and alkaline phosphatase activity up to 2-fold. Pamidronate has a more pronounced calcium-lowering effect than either titanium acid and clodronic acid) and provides normocalcaemic relief over a longer period of time. Pamidronate(APD) dose-dependently inhibited the uptake of calcium phosphate film by horse osteoclast-like cells with an IC50 of 0.58 μm. Pamidronate dose-dependently suppressed the number of osteoclast-like cells after 7 days of bone marrow culture. |
In vivo study | Pamidronate significantly inhibited this increase below control levels in the distal femur and tibia of rats. Pamidronate significantly increased bone density and weight in sham and ovariectomized rats. Pamidronate inhibited all significant effects of growth hormone (GH) in growth hormone (GH) treated rats, which also reduced levels by IGF-I. Pamidronate itself increases bone density and weight of the tibia, reduces urinary DPD excretion. |
Hazard Symbols | Xn - Harmful |
Risk Codes | R22 - Harmful if swallowed R48 - Danger of serious damage to health by prolonged exposure R41 - Risk of serious damage to eyes R37/38 - Irritating to respiratory system and skin. R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. |
Safety Description | S22 - Do not breathe dust. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
UN IDs | 3077 |
WGK Germany | 3 |
RTECS | SZ6525000 |
HS Code | 29319090 |
Hazard Class | IRRITANT |
Crystal, melting point 227~229 °c.
The aqueous solution of chlorobenzene and β-aminopropionic acid was heated to 100 ° C., phosphorus trichloride was added dropwise with stirring, and the reaction was further incubated. After cooling to room temperature, hydrogen chloride gas was removed by chlorine gas. The chlorobenzene solution was separated and slowly dripped. The mixture was stirred and heated to 100 °c for reaction. The crystals were crystallized by freezing, filtered, and the phosphonic acid was obtained. Pamidronate was suspended in water, and sodium hydroxide was added dropwise. The crystals were cooled and precipitated, filtered, and the filter cake was treated to obtain pamidronate disodium pentahydrate.
This product is disodium 3-amino -1-hydroxypropylidene diphosphonate pentahydrate. Calculated as dried product, the content of C3H9NNa207P2 shall not be less than 98.0%.
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.709 ml | 13.546 ml | 27.092 ml |
5 mM | 0.542 ml | 2.709 ml | 5.418 ml |
10 mM | 0.271 ml | 1.355 ml | 2.709 ml |
5 mM | 0.054 ml | 0.271 ml | 0.542 ml |
developed by the Swiss company Ciba-Geigy, launched in 1989. Potent inhibitors of Osteoclastic bone resorption. Sodium pamidronate inhibits the attachment of osteoclast precursors to bone and their transformation into mature, functional osteoclasts. Both in vivo and in vitro, it has a local and direct anti-bone resorption effect of the bone-bound bisphosphonate. For tumor hyperemia, Paget's disease, malignant tumor and normal blood calcium osteolytic bone metastasis, idiopathic osteoporosis. Significant effect, low side effects.
take l.Og of this product, add 50ml of water to dissolve, and measure it according to law (General rule 0631). The pH value should be 7.3~8.3.
take this product l.Og, add water 25ml after dissolution, the solution should be clear and colorless.
take this product about 3.2g, precision weighing, put 250ml iodine bottle, add water 70ml to dissolve, add phosphate buffer (pH 7.3)(take sodium dihydrogen phosphate 6.9g, add water to dissolve into 500ml, add 0.1 mol/L sodium hydroxide solution 400ml, shake well) 20ml, with 6mol/L acetic acid solution to adjust the pH value to 7.3 0.2, precision Iodine titration solution (0.05mol/L) 20ml, shake well, after standing in the dark for 1 hour, add 0.5ml of 6mol/L acetic acid solution, immediately use sodium thiosulfate titration solution (0.1 mol/L) titration, to the near end point, add 2ml of starch indicator solution, continue titration to blue disappeared, and the titration result is corrected by blank test. Each 1 ml of Iodine titration solution (0.05mol/L) is equivalent to mg of NaH2P03. The content of NaH2P03 should not exceed 0.5%.
take this product, precision weighing, water dissolution and quantitative dilution made in each lml containing about 3.0 mg of solution, take 2ml, put it in a 10ml measuring flask, add 3ml of water, 1.0ml of 5% sodium carbonate solution and 2, 4-dinitrofluorophenylacetonitrile solution (take 2, the appropriate amount of 4-dinitrofluorobenzene was dissolved in acetonitrile and diluted to prepare a solution containing 15mg of 2, 4-dinitrofluorobenzene per 1 ml) 2.0ml, shake well, after reacting in a water bath at 40°C for 2 hours, take it out, let it cool down, dilute it to the scale with water, shake it well, and use it as a test solution, water was added to dissolve and quantitatively diluted to prepare a solution containing about 9ug per 1 ml, and 2ml was accurately measured to prepare a reference solution by the same method. According to the high performance liquid chromatography (General 0512) test, with eighteen alkyl silane bonded silica gel as filler, 0.01mol/ L potassium dihydrogen phosphate buffer (with sodium hydroxide solution to adjust the pH to 7.0) -methanol (70:30) as the mobile phase, the column temperature is 40°C, the detection wavelength is 360nm, the number of theoretical plate is not less than 2000 according to the calculation of the peak of the alanine derivative. The sample solution and the reference solution were respectively 10 u1, injected into the human liquid chromatograph, and the chromatogram was recorded. If there is a chromatographic peak in the chromatogram of the test solution that is consistent with the retention time of the peak of the alanine derivative, the peak area shall be calculated according to the external standard method, and shall not exceed 0.3%.
take this product about 0.5g, at 160 deg C dry 20 hours, weight loss should be 23.0% ~ 25.0% (General 0831).
take 1.0g of this product, add 23ml of water to dissolve, add 2ml of acetate buffer (pH 3.5), and check according to law (General rule 0821 first law), containing heavy metals shall not exceed 10 parts per million.
take this product about 0.25g, precision weighing, add water 70ml dissolved, according to the potential titration method (General rule 0701), with hydrochloric acid titration solution (0.1 mol/L) titration and the results of the titration were corrected with a blank test. Each 1 ml of hydrochloric acid titration solution (0.1 mol/ L corresponds to 27.91mg of C3H9N Na207P2.
calcium modulator.
sealed storage.
This product is a sterile aqueous solution of pamidronate disodium with an appropriate amount of mannitol. Disodium pamidronate anhydrous (C3H9NNa207P2) shall be present at 90.0% to 110.0% of the labeled amount.
This product is a clear colorless liquid.
with pamidronate disodium.
specification
5ml:15mg (C3H9NNa207P2)
sealed storage.